SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending due to discussions around a potential acquisition deal falling through, leading to price volatility. The community is debating the implications of this failed deal, particularly regarding the company's future prospects and potential government support, in light of its position in the antimony market amid ongoing concerns about supply chain independence from China. Traders are also actively discussing technical analysis, potential entry points, and the stock's overall long-term value.

Trump For President

The price of TRUMP CRYPTO is volatile as traders debate its potential, with some citing exhaustion of sellers while others point to corruption and call it a scam. Community members are expressing strong opinions, with some predicting a short squeeze and others anticipating a crash. Broader market factors and political events seem to be influencing the coin's movements.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending due to its entrance into the AI chip market, highlighted by the launch of new AI200 and AI250 chips aimed at data centers, positioning it as a competitor to Nvidia and AMD. Community discussions revolve around the potential impact of these chips, particularly their power efficiency and customer base, with some analysts expressing skepticism about revenue projections. The move signifies Qualcomm's diversification beyond mobile chips into the growing AI infrastructure sector.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending amid discussions about a potential activist investor campaign and NFL partnership, with the community debating whether these catalysts can reverse the stock's recent downturn. Some traders point to technical indicators suggesting a bottom, while others express concerns about market manipulation and the company's long-term prospects. Overall sentiment is mixed as investors weigh the potential impact of these developments on Lululemon's future performance.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending due to a temporary pause in gene therapy trials after a patient experienced a serious liver injury, leading to a significant drop in stock price. The community is debating whether this is an overreaction and a buying opportunity, with some focusing on the fact that it was a single patient out of many and the potential for trial resumption. Others are concerned about the implications for the gene editing sector and the company's cash burn.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is trending as investors anticipate Q3 earnings, focusing on the company's AI-driven growth strategy amid legacy business challenges. The community is discussing the potential impact of AI, a recent Palantir partnership, and government contracts on the stock's future. Some are speculating on price targets and a possible tech company rerating.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community rallies around a potential breakout, fueled by the optimistic "WAGMI" (We Are All Gonna Make It) sentiment. Discussions revolve around key resistance levels and the possibility of a Solana ETF, while some traders are also watching meme coins built on Solana, such as SLAP and WAGMI.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels ($UUUU) is trending as investors discuss its potential role in securing a U.S.-based rare earth supply chain, particularly in light of geopolitical tensions with China and a recent joint venture in Australia. The community is also closely watching for potential government contracts and discussing high call option activity, suggesting possible insider knowledge or a significant upcoming catalyst. Some traders express concerns about stock dilution and the company's path to profitability.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond ($BBBY) is trending as the company is changing its ticker symbol from $BYON back to $BBBY. Community members are actively discussing the potential implications of this change and its relation to meme stock status, with some drawing comparisons to the GameStop ($GME) saga and Ryan Cohen. There are also discussions around the company's blockchain assets and the potential impact of TZero.

Project Nema is a research initiative enhancing AI memory and companionship by integrating the C. elegans neural connectome with a large language model (LLM). The LLM translates human language to interact with the worm's simulated brain, addressing LLMs' lack of persistent emotional or psychological states beyond context windows. This creates a stable, evolving neural state that retains history across sessions. For example, user inputs like "good morning Nema" fetch state and history for processing. Utilities include companionship, where Nema acts as the LLM's "soul" for long-term personality building, and dynamic adaptation mimicking life. It also aims to boost LLM outputs via extended memory. The project involves user management and visualizations.

NEMA LAB

NEMA is trending as discussions highlight its AI utility and migration from the WORM project, with community members emphasizing its potential and unique technology. The migration is seen as a catalyst, with many believing NEMA can surpass WORM's previous market cap due to its added utility and 'intelligence'. It's part of a broader conversation around AI-driven crypto projects on the SOL network.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$RLAY 10/20/25 Barclays analyst Peter Lawson maintained a Buy rating on Relay Therapeutics today and set a price target of $17.00. The company’s shares closed last Friday at $6.49.

Michael DeMattia

StockTwits Web

Relay Therapeutics Inc

 10/20/25 Barclays analyst Peter Lawson maintained a Buy rating on Relay Therapeutics today and set a price target of $17.00. The company’s shares closed last Friday at $6.49.